EU focuses on safety and effectiveness of pandemic vaccines
This article was originally published in SRA
As vaccination campaigns against pandemic flu get underway, the European regulatory and health authorities have laid out their strategy for monitoring the benefit:risk profiles of the various vaccines. The emphasis will be on the rapid detection and reporting of major safety issues such as life-threatening reactions and birth defects, as well as on the effectiveness and immunogenicity of the individual vaccines.
You may also be interested in...
In addition to our daily in-depth coverage of key events relating to the COVID-19 pandemic, we’re bringing you a periodic round-up of other developments. This edition covers Europe and other countries.
The US company is bringing extra supplies of lopinavir/ritonavir into France but stresses that the combination treatment is not authorized for treating patients with the coronavirus.
As part of its efforts to preserve patient access to medicines amid the COVID-19 pandemic, Russia is planning to cap drug prices if increases of more than 30% are detected. It will also allow online sales of non-prescription drugs and may also tighten the rules on fake and substandard products.